

## REFERENCES

1. United States Pharmacopeial Convention (USP). *Compounding Compendium*. Rockville, MD: USP; 2020.
2. United States Pharmacopeial Convention (USP). USP general chapter <795> pharmaceutical compounding—nonsterile preparations. In: *USP 43–NF 38* as of June 1, 2020. Rockville, MD: USP; 2020.
3. United States Pharmacopeial Convention (USP). USP general chapter <797> pharmaceutical compounding—sterile preparations. In: *USP 43–NF 38* as of June 1, 2020. Rockville, MD: USP; 2020.
4. United States Pharmacopeial Convention (USP). USP general chapter <800> hazardous drugs—handling in healthcare settings. In: *USP 43–NF 38* as of June 1, 2020. Rockville, MD: USP; 2020.
5. United States Pharmacopeial Convention (USP). USP general chapter <825> radiopharmaceuticals—preparation, compounding, dispensing, and repackaging. In: *USP 43–NF 38* as of June 1, 2020. Rockville, MD: USP; 2020.
6. United States Pharmacopeial Convention (USP). USP general chapter <797> pharmaceutical compounding—sterile preparations. In: *USP 42–NF 37*. Second Supplement. Rockville, MD: USP; 2019.
7. Newton DW. United States Pharmacopeia chapter <797> timeline 1989 to 2013. *Int J Pharm Compd*. 2013; 17:283-8.
8. US Food and Drug Administration. Repackaging of certain human drug products by pharmacies and outsourcing facilities, 2017. [www.fda.gov/downloads/Drugs/Guidances/UCM434174.pdf](http://www.fda.gov/downloads/Drugs/Guidances/UCM434174.pdf) (accessed 2020 May 22).
9. Kienle PC. *The Chapter <800> Answer Book*. Bethesda, MD: ASHP, 2017.
10. United States Pharmacopeial Convention (USP). USP general chapter <1168> compounding for phase 1 investigational studies. In: *USP 43–NF 38* as of June 1, 2020. Rockville, MD: USP; 2020.
11. US Food and Drug Administration. Compounded drug products that are essentially copies of a commercially available drug product under section 503a of the Federal Food, Drug, and Cosmetic Act, 2018. [www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510154.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510154.pdf) (accessed 2020 May 22).
12. American Society of Health-System Pharmacists. ASHP sterile products preparation certificate program, 2019. [www.ashp.org](http://www.ashp.org) (accessed 2020 May 22).
13. CriticalPoint, LLC. Website. [www.criticalpoint.info](http://www.criticalpoint.info) (accessed 2020 May 22).
14. Board of Pharmacy Specialties. BPS board certified sterile compounding pharmacist (BCSCP). [www.bpsweb.org](http://www.bpsweb.org) (accessed 2020 May 22).
15. Pharmacy Technician Certification Board. Certified compounded sterile preparation technician™ program. [www.ptcb.org/about-ptcb/news-room/whats-new-at-ptcb/2017/12/06/ptcb-launches-certified-compounded-sterile-preparation-technician-\(cspt-\)-program](http://www.ptcb.org/about-ptcb/news-room/whats-new-at-ptcb/2017/12/06/ptcb-launches-certified-compounded-sterile-preparation-technician-(cspt-)-program) (accessed 2020 May 22).
16. Murdaugh LB. *Competence Assessment Tools for Health-System Pharmacies*. 5th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2015.
17. American Society of Health-System Pharmacists (ASHP). ASHP's Pharmacy Competency Assessment Center. Bethesda, MD: ASHP; 2019.

18. United States Department of Labor, Occupational Safety and Health Administration. Hazard communication. [www.osha.gov/dsg/hazcom/HCSFinalRegTxt.html](http://www.osha.gov/dsg/hazcom/HCSFinalRegTxt.html) (accessed 2020 May 22).
19. Centers for Disease and Control Prevention. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. Publication number 2016-161. [www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf](http://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf) (accessed 2020 May 22).
20. United States Department of Labor, Occupational Safety and Health Administration. Hazard communication: small entity compliance guide for employers that use hazardous chemicals. [www.osha.gov/Publications/OSHA3695.pdf](http://www.osha.gov/Publications/OSHA3695.pdf) (accessed 2020 May 22).
21. Centers for Disease Control and Prevention. Hand hygiene in healthcare settings. [www.cdc.gov/handhygiene](http://www.cdc.gov/handhygiene) (accessed 2020 May 22).
22. ASTM International. ASTM D6978 standard practice for assessment of resistance of medical gloves to permeation by chemotherapy drugs. [www.astm.org/Standards/D6978.htm](http://www.astm.org/Standards/D6978.htm) (accessed 2020 May 22).
23. ASTM F739-12e1. Standard Test Method for Permeation of Liquids and Gases through Protective Clothing Materials under Conditions of Continuous Contact. West Conshohocken, PA: ASTM International.
24. Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. The national personal protective technology laboratory, respirator trusted-source information. [www.cdc.gov/niosh/npptl/topics/respirators/disp\\_part/respsource.html](http://www.cdc.gov/niosh/npptl/topics/respirators/disp_part/respsource.html) (accessed 2020 May 22).
25. Centers for Disease Control and Prevention. Safe injection practices to prevent transmission of infections to patients. [www.cdc.gov/injectionsafety/ip07\\_standardprecaution.html](http://www.cdc.gov/injectionsafety/ip07_standardprecaution.html) (accessed 2020 May 22).
26. Association for Professionals in Infection Control and Epidemiology. APIC position paper: safe injection, infusion, and medication vial practices in health care (2016). [www.apic.org/Resource\\_/TinyMceFileManager/Position\\_Statements/2016APICSIPPpositionPaper.pdf](http://www.apic.org/Resource_/TinyMceFileManager/Position_Statements/2016APICSIPPpositionPaper.pdf) (accessed 2020 May 22).
27. Buchanan C, Schneider P, Forrey R. *Compounding Sterile Preparations*. 4th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2017.
28. United States Pharmacopeial Convention (USP) general chapter <71> sterility tests. In: *USP 43-NF 38* as of June 1, 2020. Rockville, MD: USP; 2020.
29. US Food and Drug Administration. FD&C Act provisions that apply to human drug compounding. [www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm606955.htm](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm606955.htm) (accessed 2020 May 22).
30. United States Pharmacopeial Convention (USP). USP general chapter <1231> water for pharmaceutical purposes. In: *USP 43-NF 38* as of June 1, 2020. Rockville, MD: USP; 2020.
31. Controlled Environment Testing Association. CETA application guides. [www.cetainternational.org](http://www.cetainternational.org) (accessed 2020 May 22).
32. Institute for Safe Medication Practices. Guidelines for safe preparation of compounded sterile preparations. [www.ismp.org/guidelines/sterile-compounding](http://www.ismp.org/guidelines/sterile-compounding) (accessed 2020 May 22).
33. United States Pharmacopeial Convention (USP). USP general chapter <659> packaging and storage requirements. In: *USP 43-NF 38* as of June 1, 2020. Rockville, MD: USP; 2020.
34. Rhoads R, Exner L, Wagner JT. Demystifying dynamic smoke pattern tests for sterile compounding pharmacies. *Am J Health-Syst Pharm*. 2020;77:56-60.

35. US Food and Drug Administration. Bulk drug substances used in compounding under section 503a of the FD&C Act. [www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm614204.htm](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm614204.htm) (accessed 2020 May 22).
36. US Food and Drug Administration. Regulatory policy information. [www.fda.gov/drugs/human-drug-compounding/regulatory-policy-information](http://www.fda.gov/drugs/human-drug-compounding/regulatory-policy-information) (accessed 2020 May 22).
37. United States Pharmacopeial Convention (USP). USP general chapter <1178> good repackaging practices. In: *USP 43–NF 38* as of June 1, 2020. Rockville, MD: USP; 2020.
38. American Society of Health-System Pharmacists. ASHP guidelines on compounding sterile preparations. *Am J Health-Syst Pharm.* 2014; 71:145-66.
39. Power LA, Coyne JW. ASHP guidelines on handling hazardous drugs. *Am J Health-Syst Pharm.* 2018; 75:1996-2031.
40. Centers for Disease Control and Prevention. Biosafety in microbiological and biomedical laboratories (BMBL). 5th ed. [www.cdc.gov/labs/BMBL.html](http://www.cdc.gov/labs/BMBL.html) (accessed 2020 May 22).
41. International Journal of Pharmaceutical Compounding. Website. [www.ijpc.com](http://www.ijpc.com) (accessed 2020 May 22).
42. Centers for Disease Control and Prevention. Guidelines for the prevention of intravascular catheter-related infections. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5132a9.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5132a9.htm) (accessed 2020 May 22).
43. American Society of Health-System Pharmacists (ASHP). *Handbook on Injectable Drugs*. 20th ed. Bethesda, MD: ASHP; 2018.
44. Dellamorte Bing C, Nowobilski-Vasilios A. *Extended Stability for Parenteral Drugs*. 6th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2017.
45. King Guide Publications, Inc. *King Guide to Parenteral Admixtures*. Napa, CA: King Guide Publications; 2019.
46. US Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting program. [www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program](http://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program) (accessed 2020 May 22).
47. United States Pharmacopeial Convention (USP). USP general chapter <1113> microbial characterization, identification, and strain typing. In: *USP 43–NF 38* as of June 1, 2020. Rockville, MD: USP; 2020.
48. United States Pharmacopeial Convention (USP). USP general chapter <1163> quality assurance in pharmaceutical compounding. In: *USP 43–NF 38* as of June 1, 2020. Rockville, MD: USP; 2020.
49. US Food and Drug Administration. Insanitary conditions at compounding facilities. [www.fda.gov/media/124948/download](http://www.fda.gov/media/124948/download) (accessed 2020 May 22).